Toward a hepatitis C virus vaccine: The structural basis of hepatitis C virus neutralization by AP33, a broadly neutralizing antibody

Journal of Virology

Volumn 86, Issue 23, 2012, Pages 12923-12932

  Potter, Jane A ^a   Owsianka, Ania M ^b   Jeffery, Nathan ^b   Matthews, David J ^c   Keck, Zhen Yong ^d   Lau, Patrick ^d   Foung, Steven K H ^d   Taylor, Garry L ^a   Patel, Arvind H ^b  

^a UNIVERSITY OF ST ANDREWS   (United Kingdom)

^b MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

^c Centre for Therapeutics Discovery   (United Kingdom)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; EPITOPE; GLYCOPROTEIN E2; HEPATITIS C VACCINE; IMMUNOGLOBULIN F(AB) FRAGMENT; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY AP33; UNCLASSIFIED DRUG;

ANTIBODY COMBINING SITE; ANTIGEN RECOGNITION; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; HEPATITIS C VIRUS; MOLECULAR DOCKING; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; RESIDUE ANALYSIS; SENSITIVITY ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD81; CRYSTALLOGRAPHY, X-RAY; EPITOPES; HEPATITIS C; MICE; MODELS, MOLECULAR; MUTAGENESIS; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES; VIRAL PROTEINS;

HEPATITIS C VIRUS;

EID: 84869233037     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02052-12     Document Type: Article

References (54)

1. Allander T, et al. 2000. Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J. Gen. Virol. 81:2451-2459.
2. Al-Lazikani B, Lesk AM, Chothia C. 1997. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. 273:927-948.
3. Angus AG, Patel AH. 2011. Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2. Future Microbiol. 6:279-294.
4. Anonymous. 1999. Global surveillance and control of hepatitis C. Report of aWHOconsultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral Hepat. 6:35-47.
5. Bartosch B, et al. 2003. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278:41624-41630.
6. Broering TJ, et al. 2009. Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J. Virol. 83:12473-12482.
7. Chothia C, et al. 1989. Conformations of immunoglobulin hypervariable regions. Nature 342:877-883.
8. Clayton RF, et al. 2002. Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J. Virol. 76:7672-7682.
9. Dhillon S, et al. 2010. Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J. Virol. 84:5494-5507.
10. Di Lorenzo C, Angus AG, Patel AH. 2011. Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses 3:2280-2300.
11. Dubuisson J, et al. 1994. Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J. Virol. 68:6147-6160.
12. Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66:486-501.
13. Evans MJ, et al. 2007. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 446:801-805.
14. Farci P, et al. 1996. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. U. S. A. 93:15394-15399.
15. Flint M, et al. 1999. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol. 73:6235-6244.
16. Gal-Tanamy M, et al. 2008. In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc. Natl. Acad. Sci. U. S. A. 105:19450-19455.
17. Goffard A, et al. 2005. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J. Virol. 79:8400-8409.
18. Habersetzer F, et al. 1998. Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties. Virology 249:32-41.
19. Hadlock KG, et al. 2000. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J. Virol. 74:10407-10416.
20. Iro M, et al. 2009. A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication. Antiviral Res. 83:148-155.
21. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. 1991. Sequences of proteins of immunological interest, 5th ed. U.S. Department of Health and Human Services/NIH, Bethesda, MD.
22. Kato N, et al. 1993. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J. Virol. 67:3923-3930.
23. Keck ZY, et al. 2008. Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J. Virol. 82:6061-6066.
24. Keck ZY, et al. 2004. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J. Virol. 78:9224-9232.
25. Keck ZY, et al. 2011. Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations. J. Virol. 85:10451-10463.
26. Kong L, et al. 2012. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc. Natl. Acad. Sci. U. S. A. 109: 9499-9504.
27. Krey T, et al. 2010. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog. 6:e1000762. doi:10.1371/journal.ppat.1000762.
28. Krissinel E, Henrick K. 2007. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372:774-797.
29. Kuroda D, Shirai H, Kobori M, Nakamura H. 2008. Structural classification of CDR-H3 revisited: a lesson in antibody modeling. Proteins 73: 608-620.
30. Kwo PY, et al. 2010. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376:705-716.
31. Lavanchy D. 1999. The importance of global surveillance of influenza. Vaccine 17(Suppl. 1):S24 -S25.
32. Lawrence MC, Colman PM. 1993. Shape complementarity at proteinprotein interfaces. J. Mol. Biol. 234:946-950.
33. Leslie AGW, Powell HR. 2007. Processing diffraction data with MOSFLM. Evolving Methods Macromol. Crystallogr. 245:41-51.
34. Martin AC, Thornton JM. 1996. Structural families in loops of homologous proteins: automatic classification, modelling and application to antibodies. J. Mol. Biol. 263:800-815.
35. McCoy AJ, et al. 2007. Phaser crystallographic software. J. Appl. Crystallogr. 40:658-674.
36. McHutchison JG, et al. 2009. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 360:1827-1838.
37. Micallef JM, Kaldor JM, Dore GJ. 2006. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J. Viral Hepat. 13:34-41.
38. Moore JP, Sodroski J. 1996. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 70:1863-1872.
39. Murshudov GN, Vagin AA, Dodson EJ. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53:240-255.
40. Otwinowski Z, Minor W. 1997. Processing of X-ray diffraction data collected in oscillation mode. Macromol. Crystallogr. A 276:307-326.
41. Owsianka A, Clayton RF, Loomis-Price LD, McKeating JA, Patel AH. 2001. Functional analysis of hepatitis C virus E2 glycoproteins and viruslike particles reveals structural dissimilarities between different forms of E2. J. Gen. Virol. 82:1877-1883.
42. Owsianka A, et al. 2005. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J. Gen. Virol. 79:11095-11104.
43. Pang SS, et al. 2010. The structural basis for autonomous dimerization of the pre-T-cell antigen receptor. Nature 467:844-848.
44. Patel AH, Wood J, Penin F, Dubuisson J, McKeating JA. 2000. Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J. Gen. Virol. 81:2873-2883.
45. Pawlotsky JM. 2011. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 53:1742-1751.
46. Pileri P, et al. 1998. Binding of hepatitis C virus to CD81. Science 282: 938-941.
47. Ploss A, et al. 2009. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457:882-886.
48. Potter JA, Randall RE, Taylor GL. 2008. Crystal structure of human IPS-1/MAVS/VISA/Cardif caspase activation recruitment domain. BMC Struct. Biol. 8:11. doi:10.1186/1472-6807-8-11.
49. Shimizu YK, et al. 1994. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J. Virol. 68: 1494-1500.
50. Stanfield RL, Zemla A, Wilson IA, Rupp B. 2006. Antibody elbow angles are influenced by their light chain class. J. Mol. Biol. 357:1566-1574.
51. Tarr AW, et al. 2007. Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J. Gen. Virol. 88:2991-3001.
52. Tarr AW, et al. 2006. Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 43:592-601.
53. Wilson IA, Ghiara JB, Stanfield RL. 1994. Structure of anti-peptide antibody complexes. Res. Immunol. 145:73-78.
54. Winn MD, et al. 2011. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67:235-242.